Nektar Therapeutics

Nektar is enrolling Phase 3 trials for rezpegaldesleukin (rezpeg) in atopic dermatitis and alopecia areata, with top-line atopic dermatitis data expected mid-2028 and a potential BLA submission in 2029. The company reported a $1.02 billion cash balance that management says funds operations into 2028, while operating losses widened and R&D spending is guided to $210–230 million for the year. Nektar raised $373.8 million in April through a public offering, faces a federal jury trial in September 2026, and carries elevated short interest as investors wait for pivotal data. » Mere på finance.yahoo.com

Nektar reported an adjusted loss of $1.23 per share for Q2, beating the consensus estimate of $2.00, while revenue of $10.13 million came in just below expectations. The company ended the quarter with $1.02 billion in cash and investments and expects those funds to last into the third quarter of 2028. Nektar is advancing lead candidate REZPEG in Phase III trials for atopic dermatitis and alopecia areata; key Phase III data for dermatitis are expected in mid-2028. Despite the earnings beat, the stock fell after hours as investors weighed the revenue miss, the long approval timeline and valuation risks. » Mere på de.investing.com

Nektar Therapeutics is concentrating on developing and out-licensing drug candidates, with lead compound REZPEG at the center for targeted immune modulation. REZPEG targets large markets such as atopic dermatitis and alopecia areata. With a liquidity reserve of more than $1 billion, the company is financially positioned to continue clinical research through at least 2028. » Mere på finanzen.net

Nektar Therapeutics confirmed it will start the Phase 3 ZENITH-AD program for rezpegaldesleukin in July 2026, comprising five trials with the first readout expected in mid-2028. Analysts are split: Wedbush cut its price target to $80 and kept a Neutral rating, citing concerns about Dupixent’s market dominance and upcoming biosimilars, while Piper Sandler raised its target to $192 and retained an Overweight rating. The company also reaffirmed forward guidance and continues development across multiple immunology and oncology candidates. » Mere på finance.yahoo.com

Patient Square Capital disclosed a new position of 210,000 shares of Nektar Therapeutics, an estimated $11.96 million purchase that represented 2.68% of its reportable AUM and held a quarter-end value of $15.11 million. Nektar shares have surged year‑over‑year after positive phase 2b Rezolve‑AD results for rezpegaldesleukin, and the company plans to advance the asset into phase 3 with a potential BLA filing in 2029. As of May 14, 2026, Nektar shares traded around $74.33 and the company remains a clinical‑stage biopharma focused on cytokine‑based immunotherapies. » Mere på finance.yahoo.com